The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]

Simon P. L. Travis, a Dan Schnell, b Brian G. Feagan, c Maria T. Abreu, d Douglas G. Altman, e Stephen B. Hanauer, f Piotr Krzeski, g Gary R. Lichtenstein, h Philippe R. Marteau, i Jean-Yves Mary, j Walter Reinisch, k Bruce E. Sands, l Patrick Schnell, m Bruce R. Yacyshyn, n Jean-Frédéric Colombel, o Christian A. Bernhardt, p William J. Sandborn q

Abstract

Background and Aims: To determine whether clinical information influences endoscopic scoring by central readers using the Ulcerative Colitis Endoscopic Index of Severity [UCEIS; comprising ‘vascular pattern’, ‘bleeding’, ‘erosions and ulcers’].

Methods: Forty central readers performed 28 evaluations, including 2 repeats, from a library of 44 video sigmoidoscopies stratified by Mayo Clinic Score. Following training, readers were randomised to scoring with [‘unblinded’, n = 20, including 4 control videos with misleading information] or without [‘blinded’, n 20] clinical information. A total of 21 virtual Central Reader Groups [CRGs], of three blinded readers, were created. Agreement criteria were pre-specified. Kappa [κ] statistics quantified intra- and inter-reader variability.

Results: Mean UCEIS scores did not differ between blinded and unblinded readers for any of the 40 main videos. UCEIS standard deviations [SD] were similar [median blinded 0.94, unblinded 0.93; p = 0.97]. Correlation between UCEIS and visual analogue scale [VAS] assessment of overall severity was high [r blinded = 0.90, unblinded = 0.93; p = 0.02]. Scores for control videos were
similar [UCEIS: $p \geq 0.55$; VAS: $p \geq 0.07$]. Intra- [κ 0.47–0.74] and inter-reader [κ 0.40–0.53] variability for items and full UCEIS was ‘moderate’-to-‘substantial’, with no significant differences except for intra-reader variability for erosions and ulcers [κ blinded: 0.47 vs unblinded: 0.74; $p = 0.047$. The SD of CRGs was lower than for individual central readers [0.54 vs 0.95; $p < 0.001$. Correlation between blinded UCEIS and patient-reported symptoms was high [stool frequency: 0.76; rectal bleeding: 0.82; both: 0.81].

**Conclusions:** The UCEIS is minimally affected by knowledge of clinical details, strongly correlates with patient-reported symptoms, and is a suitable instrument for trials. CRGs performed better than individuals.

**Keywords:** Endoscopic score; ulcerative colitis; disease activity index

---

### 1. Introduction

Endoscopy is central to the assessment of disease activity in ulcerative colitis [UC] both in trials and in clinical practice, but assessment is often inconsistent. Activity indices for UC, such as the Mayo Clinic Score, incorporate an endoscopic component and are commonly used to evaluate response to treatment in clinical trials. Lack of consistency can affect the outcomes of trials, independently of the effect of treatment, and negatively affect decisions by regulatory authorities or clinicians. The Ulcerative Colitis Endoscopic Index of Severity [UCEIS] was developed as a rigorous instrument for assessing endoscopic disease activity in UC.

The UCEIS was developed using a predefined protocol. Initially, the level of disagreement for 10 endoscopic items, each with 3–5 levels of severity, was determined among 10 investigators. The intra- and inter-investigator variability for each item was then assessed by 30 different investigators, and a model constructed that best represented overall endoscopic activity evaluated on a visual analogue scale [VAS]. The final model consisted of three items: vascular pattern [3 levels], bleeding [4 levels], and erosions and ulcers [4 levels] [Table 1]. In practice, the UCEIS is scored from the worst affected area at video sigmoidoscopy and the final score is the sum of components ranging from 0 [normal] to 8 [most severe; it should be noted that this simplifies the original index which ranged from 3–11].

The UCEIS accounted for 88% of the variance between observers in the overall assessment of endoscopic activity in the test cohort and 86% in the validation cohort.

The aim of the present study was to understand the UCEIS in a clinical context. The primary objective was to determine whether the UCEIS is affected by clinical information, using an independent cohort of central reader investigators. Henceforth, the term ‘readers’ rather than ‘investigators’ or ‘observers’ will be used for consistency, since ‘investigators’ implies clinicians who recruit patients to trials and often have knowledge of symptoms, whereas ‘readers’ implies independence from the patient, and ‘observers’ is a generic term for either. Secondary objectives were to investigate potential benefits of a group of central readers for reducing variability, and to compare scores with other indices and patient-reported symptoms.

### 2. Materials and Methods

#### 2.1. Development of the UCEIS

The development of the UCEIS has been reported. In short, the resource was a library of 670 videosigmoidoscopies from patients in three clinical trials, supplemented by individuals without UC and hospitalised patients with acute severe UC. In phase 1, the authors determined agreement in overall endoscopic assessment and defined

---

**Table 1. The UCEIS: items, levels, and definitions used as anchor points for evaluating ulcerative colitis.**

| Descriptor [score most severe lesions] | Likert scale anchor points | Definition |
|---------------------------------------|----------------------------|------------|
| Vascular pattern                      | Normal [0]                 | Normal vascular pattern with arborisation of capillaries clearly defined, or with blurring or patchy loss of capillary margins |
|                                       | Patchy obliteration [1]    | Patchy obliteration of vascular pattern |
|                                       | Obliterated [2]            | Complete obliteration of vascular pattern |
| Bleeding                              | None [0]                   | No visible blood |
|                                       | Mucosal [1]                | Some spots or streaks of coagulated blood on the surface of the mucosa |
|                                       | Luminal mild [2]           | Some free liquid blood in the lumen |
|                                       | Luminal moderate or severe [3] | Frank blood in the lumen ahead of endoscope or visible oozing from mucosa after washing intra-luminal blood, or visible oozing from a haemorrhagic mucosa |
| Erosions and ulcers                   | None [0]                   | Normal mucosa, no visible erosions or ulcers |
|                                       | Erosions [1]               | Tiny [≤ 5 mm] defects in the mucosa, of a white or yellow colour with a flat edge |
|                                       | Superficial ulcer [2]      | Larger [≥ 5 mm] defects in the mucosa, which are discrete fibrin-covered ulcers when compared with erosions, but remain superficial |
|                                       | Deep ulcer [3]             | Deeper excavated defects in the mucosa, with a slightly raised edge |

The worst affected area of the colon visible at sigmoidoscopy is scored. The copyright of UCEIS is held by Watson Laboratories, a subsidiary of Actavis Inc., as successor in interest of Warner Chilcott and Procter and Gamble.
descriptive terms ['items']. Phase 2, conducted in a separate cohort of 30 investigators, rated items in 25 of 60 different videos and assessed overall severity on a 100-point VAS [0 completely normal and 100 = worst ever seen]. The UCEIS developed from this study included three items [Table 1]. The UCEIS is freely accessible to all at no cost, though the terminology is subject to copyright and acknowledgement. Phase 3, in another cohort of 25 investigators, demonstrated reproducibility of the UCEIS in 28 of 57 videos and rebased normality to '0', rather than '3'. This paper reports phase 4, to evaluate the effect of clinical information on endoscopic scoring.

2.2. Assessment of the impact of knowledge of clinical information on UCEIS scoring

2.2.1. Investigators

A new cohort of 40 investigators ['readers'] was enrolled from Europe, North America and Australasia, all of whom were experienced in evaluating endoscopies in patients with UC. Three had previously participated in phase 2 or 3 of UCEIS development and all were blinded to the objectives of the study. To investigate the effect of clinical information on UCEIS scoring, investigators were alternately assigned to the blinded [n = 20] and unblinded [n = 20] assessment groups as they completed the study enrolment requirements [but prior to training or receipt of any study videos]. All underwent training on the UCEIS, which excluded clinical information and involved scoring four standard videos; to qualify [details in 3. Results], assessments on each video had to align with the level of 'erosions and ulcers' assigned by the authors [SPLT,PK,BRY,WJS], and within one level for vascular pattern and bleeding. For readers initially failing to qualify, a retest was permitted; they had correctly to score two of three different videos for the item[s] that they had previously scored incorrectly. Readers who failed the second qualifier were excluded.

2.2.2. Video selection

A new library of 44 anonymised videos was created from 670 videos and supplements created for phase 1–3, stratified by clinical disease activity [Mayo Clinic Score; MCS] assigned on the date that they underwent training on the UCEIS, which excluded clinical information on UCEIS scoring. Each reader performed 28 evaluations from the 44 videos, which included two repeats of non-control videos to evaluate intra-reader variation and the four common controls [Figure 1]. Readers were either provided with clinical information on disease activity for each video [one or two sentences on age, symptoms and history, summarised by PK/BRY/ST; unblinded group] or with no accompanying clinical information [blinded group]. Patient information was extracted from the original trials. To ensure some disparity between clinical information and endoscopic assessment, the two common control videos with MCS 1–2 in the unblinded group were assigned information more severe than reported [originally: rectal bleeding [RB] = 1 / stool frequency [SF] = 0 / Physician’s Global Assessment [PGA] = 0; and RB = 0/ SF = 1PGA = 0; both changed to: RB = 1/SF = 2/PGA = 1]. The two control videos with MCS 10–11 were given symptom information less severe [originally: RB = 3/SF = 3/PGA = 3; and RB = 2/SF = 3/ PGA = 3; both changed to: RB = 2/SF = 2/PGA = 2]. Readers in the blinded group were not provided with any clinical information for the common control videos, as with their other videos.

2.2.4. Video evaluation

The 40 readers who passed training evaluated the UCEIS [Table 1] in the worst area affected at video sigmoidoscopy. As with phase 3, still photographs from the training were provided for reference during the evaluations and the overall assessment of endoscopic severity recorded on a 100-point VAS [0 completely normal and 100 = worst ever seen]. Data were captured using a programme developed by one of the authors [PS] that ran simultaneously and saved responses after scoring each video.

2.3. Assessment of the potential for central reader groups to reduce overall variability

The effect of central reading to improve consistency of scoring the UCEIS was examined through ‘virtual’ central reading groups [CRGs] of three readers. Some of the readers [6/40] were recruited specifically for their experience as central readers in other trials [see acknowledgements]; three were randomly allocated to the blinded group and three to the unblinded group [Figure 1]. In the blinded group, each CRG consisted of one randomly chosen ‘experienced central reader’, together with two randomly selected ‘standard readers’ from the other seven in the group [all, therefore, scored the same
values were calculated by stratifying by reader pairs and using the
variance between qualifiers was not evaluated, because of disparity
between groups were assessed by nonparametric methods.

2.4.4. Secondary objective: comparison of UCEIS with other
indices and patient-reported symptoms

The comparative indices selected were the Mayo Clinic Score
(MCS), partial MCS [excluding endoscopic subscore], and the
modified Baron score, as recorded in the original clinical trials. To
compare the UCEIS with patient-reported symptoms and variables
recorded in practice, stool frequency [SF], rectal bleeding [RB], both
SF and RB, and patient functional assessment were derived from
subscores of the MCS contemporaneously recorded for each video.
These variables were compared with UCEIS scores for the blinded
readers, excluding those for ‘normal’ and ‘most severe’ videos [for
which there was no MCS] and common controls [which were
repeats], by Spearman rank correlation. SF, RB, PFA, and partial
MCS were also correlated with the modified Baron score, to deter-
mine how results compared with those calculated for the UCEIS.
The relationship between the UCEIS bleeding item [scored 0–3] and
patient-reported RB on a 3-point scale [0 = none to 2 = visible blood
with stool > half the time or passing blood alone] was also evaluated.
Finally, the distribution of RB, SF, and RB and SF items across UCEIS
scores 0–8 was assessed for blinded video evaluations, excluding
‘normal’, ‘most severe’, and common control videos.

Except as noted for comparison of mean scores by video, statistical
significance was assumed at the 5% level [unadjusted p < 0.05], using
the Statistical Analysis System [SAS, Cary, NC] software, version 9.2.

2.5. Ethical statement

All subjects had consented for anonymised presentation of their
video sigmoidoscopies [EUDRACT 2006-001310-32; Oxford LREC
536407Q1605/58ORH].

3. Results

3.1. Reader qualification

A total of 47 readers underwent UCEIS training to reach the target
of 40 for the study. Of those that qualified, 20 succeeded on their
initial assessment and the remainder after scoring the additional set
of 40 videos. Of those that qualified, 20 succeeded on their
initial assessment and the remainder after scoring the additional set
of 40 videos. The remaining seven physicians failed to qualify.
Variance between qualifiers was not evaluated, because of disparity
between reader numbers and variables.

3.2. Video evaluation

A total of 1120 evaluations were performed across the 44 videos [40
readers x 28 evaluations]. The main analysis dataset consisted of 880
evaluations [440 each for blinded and unblinded groups] across 40 videos,
obtained by removing evaluations of the four common control videos
and the second evaluation in each of the two repeated videos. The
data set for the four common control videos consisted of 160 evaluations
[40 readers x 4 videos]. There were also 160 evaluations in the dataset
for assessing intra-reader variability [40 readers x 2 repeat pairs].

3.3. Range of disease severity

Mean assessments of overall endoscopic severity by VAS [0–100]
ranged from 1.65 for videos in the ‘normal’ stratum to 92.75 for
videos in the ‘most severe ever seen’ stratum according to the 40
readers. Using the same videos, this corresponded to mean UCEIS
scores of 0.15/8 for ‘normal’ subjects to 7.90/8 for ‘most severe’,
indicating that the videos comprehensively covered the range of
endoscopic severity of UC [Figure 2].
3.4. Impact of knowledge of clinical information on UCEIS scoring

3.4.1. Mean agreement, variability, and correlation in UCEIS and overall severity scores

Mean UCEIS scores did not differ between blinded and unblinded readers for any of the 40 videos in the main analysis set [Wilcoxon rank sum tests with Holm’s multiplicity adjustment, all $p$-values $\geq 0.05$] [Figure 2A]. There was one video [severe UC recorded before colectomy] for which the VAS score was significantly higher in the blinded group [$p = 0.045$] [Figure 2B]. There were no systematic differences found in the UCEIS SDs between the blinded and unblinded groups in the main dataset [median SD 0.94 vs 0.93, respectively; $p = 0.97$], although as expected, the SD was lowest at the severe end of the video spectrum [Figure 3]. Median correlation between UCEIS and overall severity on the VAS was high in both the blinded [median = 0.899, minimum = 0.80, maximum = 0.967] and unblinded [median = 0.933, minimum = 0.856, maximum = 0.972] groups in the main dataset of 40 videos. The difference between the median correlations, though small [0.034], was statistically significant [$p = 0.02$]. For the four common control videos, there were no statistically significant differences in UCEIS [$p \geq 0.55$] or overall severity scores [$p \geq 0.07$] between reader groups.

3.4.2. Intra-reader and inter-reader agreement

Overall, intra-reader variability for the three items ranged from $\kappa$ 0.47 to 0.74, indicating ‘moderate’ to ‘substantial’ agreement [Table 2]. Intra-reader agreements for ‘vascular pattern’ and ‘bleeding’ items were similar for the blinded and unblinded groups, whereas the difference for the ‘erosions and ulcers’ item [blinded: $\kappa$ 0.47 vs unblinded: $\kappa$ 0.74; $p = 0.047$] just reached statistical significance. Clinical information tended to increase variability [i.e. reduced the $\kappa$] for the bleeding item and improved consistency between readers for erosions and ulcers. Weighted intra-reader kappas for the full
UCEIS [sums of the three descriptors] were 0.51 (95% confidence interval [CI] = 0.36, 0.66) and 0.56 (95% CI = 0.42, 0.69) for the blinded and unblinded readers, respectively, and were not significantly different ($p = 0.66$).

Inter-reader agreement for the items was also ‘moderate’ to ‘substantial’ [$\kappa$ 0.40 to 0.71; Table 3]. There were no significant differences in inter-reader variability between blinded and unblinded groups for any of the items, whether analysed within the 40 videos in the main dataset [excluding the four common control videos and the second evaluation in each of the two repeated videos] or across the four common control videos. Weighted inter-reader kappas for the full UCEIS were 0.47 [95% CI = 0.46, 0.49] and 0.47 [95% CI = 0.44, 0.50] for the blinded and unblinded readers, respectively.

3.5. Potential benefits of central reader groups to reduce overall variability

The median SD was significantly lower in the blinded, virtual CRG than for ‘standard’ readers [0.54 vs 0.95, respectively; $p < 0.001$]. This was most apparent in videos representing UCEIS scores between 3 and 5, most likely to represent the spectrum mild or moderate endoscopic disease severity [Figure 4], which has substantial implications for clinical trials. The SD was least and also most similar at the extremes of the UCEIS range [≤ 2 and ≥ 6], which implies that the UCEIS has least variance for defining remission or severe endoscopic activity.

3.6. Comparison with patient-reported symptoms and established indices

Correlation of UCEIS scores with contemporaneously recorded symptoms and indices ranged from 0.76 for stool frequency [SF, 95% CI = 0.72–0.80] or patient functional assessment [PFA, 95% CI: % 0.71, 0.79], through 0.81 for both stool frequency and rectal bleeding [SF and RB, 95% CI = 0.77, 0.84] to 0.82 for RB [95% CI = 0.78–0.85] and 0.86 for the full MCS [95% CI = 0.83, 0.88 Table 4]. The modified Baron Score consistently correlated less well than the UCEIS with all patient-reported symptoms [Table 4]. It was not possible to compare UCEIS with MCS in this regard, since patient-reported symptoms were derived from data used to calculate the MCS. When endoscopic bleeding was scored 0 on the UCEIS [none], this corresponded to patient-reported RB of 0 or 1 approximately 95% of the time, scored on a 3-point scale [above]. Similarly, when bleeding was scored ≥ 2 on the UCEIS [some free liquid blood to frank bleeding], patients reported RB > 80% of the time.

Scores for RB and SF items showed a clear correlation with endoscopic severity as measured by the UCEIS [Figure 5]. When the UCEIS score was ≥ 5, then RB or an increase in SF was present at least 95% of the time. Such patient-reported symptoms inform clinical thresholds of the UCEIS for evaluating its relationship to outcomes, which are relevant to regulatory assessment.
## 4. Discussion

This study shows that clinical information has minimal impact on endoscopic scoring of disease activity determined by the UCEIS. It also characterises the performance of the UCEIS with regard to patient-reported symptoms and the impact of central reading. In an independent cohort of 40 central readers completing 28 evaluations from a new library of 44 videos, clinical information did not produce a significant change in the UCEIS in any video [0/40]. The UCEIS correlated well with patient-reported symptoms of stool frequency and rectal bleeding [or both], such that when endoscopic bleeding was scored 0 on the UCEIS [none], this corresponded to contemporaneously patient-reported RB of 0 or 1 in 95% of the time. The UCEIS had least variance for defining remission or severe endoscopic activity, but where variance was greatest [mild-moderate activity, UCEIS 3–5], central reading by a group of three readers had most impact. Central reading matters for clinical trial design, whereas the lack of impact on symptoms on endoscopic assessment matters in clinical practice.

The collective performance of the three items accounts for 86% of the variance in the overall assessment of endoscopic severity.4 Agreement in scoring of individual items is modest but it is the overall score that matters most, assessed in the most severely affected area at flexible sigmoidoscopy. In this study, the intra- [κ 0.47 to 0.74] and inter-reader [κ 0.40 to 0.50] agreement for the three components of the UCEIS [vascular pattern, bleeding, and erosions and ulcers] was consistent with that reported in phase 3 [intra: κ 0.47 to 0.87; inter: κ 0.48 to 0.54]. Although the impact of training was not quantified in this study, it was considered appropriate as with any descriptive process such as endoscopy reporting. Consistency highlights a strength of the UCEIS in providing a simple, standardised reporting system for the endoscopic appearances of UC and confirms that it is a reliable instrument for assessing endoscopic disease severity.

The influence of clinical information had minimal effect on the variability and reproducibility of UCEIS scoring. No significant differences between readers were demonstrated for any of the items, whether readers were provided with clinical information or not [vascular pattern: κ 0.53 vs 0.50, respectively; bleeding κ 0.44 vs 0.40; erosions and ulcers: 0.47 vs 0.48]. This is internally consistent with the finding that providing unblinded readers with clinical information apparently too severe or too mild for the common control videos did not influence their scoring of the items compared with blinded readers [vascular pattern: 0.66 vs 0.67, respectively; bleeding κ 0.56 vs 0.55; erosions and ulcers: 0.66 vs 0.71]. Although the items of ‘erosions and ulcers’ registered statistical significance [blinded intra-reader κ = 0.47 vs unblinded: κ = 0.74; p = 0.047; Table 2], the confidence intervals are wide and consistent with ‘moderate’ to ‘substantial’ agreement whether blinded or unblinded to clinical information when viewing the videos. It will be difficult to improve on an index that [overall] accounts for 86% of variance between readers for the assessment of endoscopic disease activity. A Delphi procedure on the videos with most disagreement might further enhance agreement, but given the range of analyses conducted herein, some of the differences may be chance findings.

The UCEIS correlated well with patient-reported symptoms, including rectal bleeding, stool frequency [or both] and patient functional assessment [rank correlations 0.76 to 0.82]. There were strong correlations between the scores for individual items and overall UCEIS [Figure 5], encouraging application in clinical practice. There was also ‘substantial’ correlation [0.78 to 0.86] with established

### Table 3. Inter-reader agreement (κ) for UCEIS items in blinded and unblinded groups

| Item | Common control dataset | Main analysis dataset |
|------|------------------------|-----------------------|
| Vascular pattern | [0.54, 0.62] | [0.49, 0.59] |
| Bleeding | [0.48, 0.56] | [0.45, 0.52] |
| Erosions and ulcers | [0.52, 0.66] | [0.48, 0.52] |
| UCEIS | [0.59, 0.71] | [0.54, 0.62] |

*Note: κ-weighted kappa (weight of 1 for perfect agreement; 0.5 for difference in level of 1; and 0 otherwise).*

A total of 160 evaluations [40 readers x 4 videos] was consistent with that reported in phase 3 [intra: κ 0.47 to 0.87; inter: κ 0.48 to 0.54]. Although the impact of training was not quantified in this study, it was considered appropriate as with any descriptive process such as endoscopy reporting. Consistency highlights a strength of the UCEIS in providing a simple, standardised reporting system for the endoscopic appearances of UC and confirms that it is a reliable instrument for assessing endoscopic disease severity.

The influence of clinical information had minimal effect on the variability and reproducibility of UCEIS scoring. No significant differences between readers were demonstrated for any of the items, whether readers were provided with clinical information or not [‘vascular pattern’: κ 0.53 vs 0.50, respectively; ‘bleeding’ κ 0.44 vs 0.40; ‘erosions and ulcers’: 0.47 vs 0.48]. This is internally consistent with the finding that providing unblinded readers with clinical information apparently too severe or too mild for the common control videos did not influence their scoring of the items compared with blinded readers [vascular pattern: 0.66 vs 0.67, respectively; bleeding κ 0.56 vs 0.55; erosions and ulcers: 0.66 vs 0.71]. Although the items of ‘erosions and ulcers’ registered statistical significance [blinded intra-reader κ = 0.47 vs unblinded: κ = 0.74; p = 0.047; Table 2], the confidence intervals are wide and consistent with ‘moderate’ to ‘substantial’ agreement whether blinded or unblinded to clinical information when viewing the videos. It will be difficult to improve on an index that [overall] accounts for 86% of variance between readers for the assessment of endoscopic disease activity. A Delphi procedure on the videos with most disagreement might further enhance agreement, but given the range of analyses conducted herein, some of the differences may be chance findings.

The UCEIS correlated well with patient-reported symptoms, including rectal bleeding, stool frequency [or both] and patient functional assessment [rank correlations 0.76 to 0.82]. There were strong correlations between the scores for individual items and overall UCEIS [Figure 5], encouraging application in clinical practice. There was also ‘substantial’ correlation [0.78 to 0.86] with established
S. Travis et al.

Clinical indices (Mayo Clinic Score [MCS], partial MCS [excluding endoscopy], and modified Baron Score, Table 4). The UCEIS consistently correlated more strongly than the modified Baron score with all patient-reported symptoms. Unfortunately, a comparison between the UCEIS and the MCS for patient-reported symptoms was not possible, since these were derived from data used to calculate the MCS. The impact of patient symptoms on the endoscopic subscore of the MCS is not known. On the other hand, an independent comparative study on responsiveness using clinical trial data suggests that the UCEIS is marginally but consistently more responsive than the MCS. This may have an advantage in early-phase drug development. It is in this field that a binary endpoint of remission/no remission is inefficient and there is value in assessing relative changes in mean scores.16

This study has shown that variation is both least and most similar for blinded/unblinded groups at the extremes of the UCEIS range [≤ 2 and ≥ 6]. It means that the UCEIS has least variance for defining either remission or severe endoscopic activity. This is an asset when determining responsiveness [the ability to detect change], which was not evaluated in this or previous studies. Relevant to clinical trials, however, is the variance in the mid range [UCEIS 3–5], which was significantly reduced by central reading groups. This was assessed through random groups of three readers, one of whom was ‘experienced’ in central reading, to act as an adjudicator should there be disagreement between ‘standard’ readers, representing normal investigators. Central reading of endoscopy can affect the outcome of clinical trials in mildly-moderately active UC. A study of a well-established mesalazine product for mild-moderately active UC did not reach significance compared with placebo [p = 0.069].7 After blinded central reading of endoscopic videos had excluded 31% of patients for being ineligible for the criterion of a MCS subscore of > 2, the difference between the treatment groups readily achieved significance [29.0% vs 13.8%; p = 0.011]. This has implications for a charter on central reading, since the optimal configuration of central reading for scoring is unknown.9 Options include an index reader, polling multiple central reader results, adjudicating reads on ‘outliers’, or random selection of videos to be read centrally. The effect of training and revalidation on central readers needs to be determined, since all factors will affect conclusions on drug efficacy and registration.

What still needs to be defined are the levels of the UCEIS for remission, mild, moderate, and severe disease. Taking account of the variance and performance characteristics, the authors speculate that a UCEIS of 0–1 indicates remission and > 6 represents a threshold for

Table 4. Spearman rank correlations of other indices and clinical information with the UCEIS.

| Comparator                                      | Correlation [95% CI] with UCEIS | Correlation [95% CI] with Modified Baron Score<sup>a</sup> |
|-------------------------------------------------|---------------------------------|------------------------------------------------------------|
| Full MCS<sup>a</sup> [including endoscopy]      | 0.86 [0.83, 0.88]               | N/A<sup>b</sup>                                           |
| Partial MCS [excluding endoscopy]               | 0.82 [0.79, 0.85]               | 0.77 [0.61, 0.88]                                         |
| Stool frequency subscore                        | 0.76 [0.72, 0.80]               | 0.73 [0.53, 0.85]                                         |
| Rectal bleeding subscore                        | 0.82 [0.78, 0.85]               | 0.74 [0.54, 0.85]                                         |
| Both stool frequency and rectal bleeding        | 0.81 [0.77, 0.84]               | 0.77 [0.58, 0.87]                                         |
| Patient functional assessment subscore          | 0.76 [0.71, 0.79]               | 0.52 [0.24, 0.72]                                         |
| Modified Baron score<sup>a</sup>                | 0.78 [0.74, 0.81]               | -                                                          |

Analyses excluded the ‘normal’ and ‘most severe’ videos, as Mayo and PFA data were unavailable, and the common controls videos.

<sup>a</sup>MCS, Mayo Clinic Score; 95% CI, 95% confidence interval.

<sup>b</sup>Modified Baron score as determined by blinded central reader in clinical trials.

<sup>c</sup>N/A, not appropriate since Modified Baron Score from central reader is 1 of the 4 summed quantities in the MCS.
Clinical Activity and the UCEIS

severe disease with prognostic implications, although thresholds and their implications need to be defined by prospective study in clinical trials, currently in progress. A score of 0 is likely to become the aspirational goal for both regulatory trials and clinical care, which should be index independent, since remission is remission. On the other hand, the UCEIS also seems likely to become the favoured instrument for early drug development, when a binary endpoint of remission/no remission is not efficient and there is enormous value in assessing relative changes in mean scores. Further limitations of the current study are that the readers in this study may not reflect endoscopists in clinical practice. Readers were selected, trained, and had images available during the rating, so the question of whether clinical information has an impact in real life may be questioned. The answer is training. Although the UCEIS is simple in concept and easy to apply, that 7/47 proposed readers failed to agree with defined interpretations indicates that training is a necessary component of its application, no less for evaluating colitis than for endoscopic polyp detection.

Next steps in the development of the UCEIS include establishing thresholds for remission and severity, and responsiveness to change. It would be valuable to examine how the UCEIS is affected by evaluation of colonic segments at full colonoscopy. On the other hand, caution should be exercised to prevent the UCEIS becoming more complex than necessary. Of greater interest is correlation with histological disease activity or biomarkers, especially for the prognostic value in remission. Central readers can markedly decrease the variability in UCEIS scoring, particularly in the mild-moderate disease spectrum, which is most relevant to clinical trials. The UCEIS is simple to use, derived from the sum of just three items, and accurately accounts for a widest range of disease severity associated with UC, is affected minimally if at all by clinical information, and is ready for practice after appropriate training.

Conflicts of interest

None declared.

Figure 5. Distribution of rectal bleeding (RB) and stool frequency (SF) items across UCEIS levels. A: When UCEIS ≤ 1, no RB > 95% of the time; when UCEIS ≥ 6, some RB 95% of the time. B: When UCEIS ≤ 1, no increase in SF ~ 90% of the time; when UCEIS ≥ 5, increase in SF 95% of the time.
Acknowledgments

This work was supported by Warner Chilcott/Actavis. Sponsors paid for video image preparation, logistical support, statistical programming, editorial support, Open Access publication, and for the time spent by independent gastroenterologists to evaluate the UCEIS. All authors gave freely of their time and have received no remuneration for the development, reliability assessment, or validation of this index.

We are particularly grateful to the investigators who evaluated the video endoscopies, including the following experts in central reading. From North America: Edward Loftus, Rochester MN; Europe: Bernd Bokemeyer, Minden, Germany; Gert Van Assche, Leuven, Belgium; Philippe Marteau, Paris, France; Marc Ferrante, Leuven, Belgium; Australia: Ian Lawrance, Fremantle, Australia. Editorial support was provided by Strategen Ltd. Biostatistical advice was independent and conducted by the sponsors of the study [Warner Chilcott]. UCEIS copyright is registered to Warner Chilcott/Actavis on the principle that there is unrestricted access to the UCEIS®.

Author contributions

ST, PK, DS, CB, BY, and WS contributed to the concept and design of the study. DS performed the statistical analysis with further evaluation by JYM. PK, BY, and CB coordinated the planning and implementation of the study. and input from DA. PS created the data capture program for video evaluation. ST, MA, JFC, BF, SH, GL, PM, WR, BS, BY, JYM, and WS contributed to the concept and design of the study. DS performed the statistical analysis with further evaluation by JYM.

References

1. Orlandi F, Brunelli E, Feliciangeli G, et al. Observer agreement in endoscopic assessment of ulcerative colitis. Ital J Gastroenterol Hepatol 1998;30:539–41.
2. de Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol 2004;4:9.
3. Travis SPL, Cooney R, Lukas M, et al. Conduct of clinical trials in ulcerative colitis: impact of independent scoring of endoscopic severity on results of a randomised controlled trial with a peptide and SASA. Am J Gastroenterol 2006;101:S429.
4. Walsh AJ, Ghosh A, Brain A, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 2014;8:318–25.
5. Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity [UCEIS]. Gut 2012;61:535–42.
6. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–6.
7. Feagan BG, Sandborn WJ, D’Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149–57.
8. Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the Ulcerative Colitis Endoscopic Index of Severity. Gastroenterology 2013;145:987–95.
9. Gottlieb K, Travis SPL, Sandborn WJ, Hussain F, Feagan BG, Rutgeerts P. Clinical trial endoscopy and central reading of endoscopy endpoints for inflammatory bowel disease. Inflamm Bowel Dis 2015 [in press].
10. Travis SPL, Yap LM, Hawkey CJ, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis [UC]: results of parallel prospective, multicenter, blinded, placebo-controlled trials. Inflamm Bowel Dis 2005;11:713–9.
11. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8g/day [800-mg tablet] is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934–43.e1-3.
12. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.
13. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363–74.
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
15. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660–6.
16. Levesque BG, Lofrus EV, Panaccione R, et al. PI50 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis. J Crohns Colitis 2014;8:S124.
17. Corte CJ, Fernandopulle N, Catuncau A, et al. Correlation between the Ulcerative Colitis Endoscopic Index of Severity [UCEIS] and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015 March 13. pii: mv047. [Epub ahead of print.]
18. Peyrin Biroulet L, Sandborn WJ, Sands B, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]: determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015 [in press].
19. Samuel S, Brunning DH, Lofrus EV, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11:49–54.
20. Thia KT, Lofrus EV, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011;17:1257–64.